Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SENSIENT TECHNOLOGIES CORPSXT · Entity 3822 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SENSIENT TECHNOLOGIES CORP
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred StockSEC Table II · derivative / convertible security | Direct | 24,516.786 |
Reported balance
After 2026-09-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-30 · Grant · Acquired 279.414 · Balance 24,516.786 F2: Deferred stock converts to common stock on a one-for-one basis. F3: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 23,789.02 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 23,789.02 F1: Includes shares of restricted stock held under Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares of restricted stock held under Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan.
F2: Deferred stock converts to common stock on a one-for-one basis.
F3: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan.
F4: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avid Bioservices, Inc.
Report date February 05, 2025 · Filed February 07, 2025
Section 16 reporting ended · disclosed 2025-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 1
1 source rowRow 1 · 2025-02-05 · Disposition to issuer · Disposed 130,324 · Balance 0 F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2027-11-27 | Direct | 49,305 |
Reported balance
After 2025-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-05 · Disposition to issuer · Disposed 75,000 · Balance 49,305 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2025-12-14 | Direct | 29,705 |
Reported balance
After 2025-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-05 · Disposition to issuer · Disposed 19,600 · Balance 29,705 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 · Expires 2027-01-09 | Direct | 10,030 |
Reported balance
After 2025-02-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-05 · Disposition to issuer · Disposed 19,675 · Balance 10,030 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2027-12-14 | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-05 · Disposition to issuer · Disposed 10,030 · Balance 0 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-05 · Disposition to issuer · Disposed 8,147 · Balance 0 F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub.
F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.
F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.
F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 01:19 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 279.414 | $0.00 | $0.00 |
DisclosureSEC source: 0000310142-26-000052 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,516.786 Underlying: Common Stock · 279.414 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:58 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 296.253 | $0.00 | $0.00 |
DisclosureSEC source: 0000310142-26-000046 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,163.893 Underlying: Common Stock · 296.253 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 16:16 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantCommon Stock | 1,119 | $0.00 | $0.00 |
DisclosureSEC source: 0000310142-26-000035 · form4.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,670.313 F1 · kind: Represents grant of restricted stock under Issuer's 2017 Stock Plan, as amended and restated. F2 · balance_after: Includes shares of restricted stock held under Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 16:29 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 422.547 | $0.00 | $0.00 |
DisclosureSEC source: 0000310142-26-000027 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,780.4 Underlying: Common Stock · 422.547 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 20:48 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 388.771 | $0.00 | $0.00 |
DisclosureSEC source: 0000310142-26-000004 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,263.025 Underlying: Common Stock · 388.771 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| November 03, 2025 Filed Nov 3, 2025 21:27 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | PurchaseCommon Stock | 1,000 | $91.26 | $91,257.50 |
DisclosureSEC source: 0000310142-25-000008 · form4.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,414.266 F1 · balance_after: Includes shares of restricted stock held under Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 21:16 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 389.185 | $0.00 | $0.00 |
DisclosureSEC source: 0000310142-25-000006 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,776.623 Underlying: Common Stock · 389.185 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 18:50 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 370.737 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-018320 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,305.754 Underlying: Common Stock · 370.737 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| April 24, 2025 Filed Apr 28, 2025 18:25 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantCommon Stock | 1,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012678 · form4.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,285.33 F1 · kind: Represents grant of restricted stock under Issuer's 2017 Stock Plan, as amended and restated. F2 · balance_after: Includes shares of restricted stock held under Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 19:42 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 490.73 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-010769 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,840.25 Underlying: Common Stock · 490.73 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:37 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerRestricted Stock Units · Derivative | 8,147 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001683168-25-000855 · ownership.xml · derivative · entry 6 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,147 shares Expires not disclosed F5 · shares: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6 · price: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. F6 · derivative.exercise_date: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. F6 · derivative.expiration_date: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:37 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerStock Option (right to buy) · Derivative | 10,030 | Not disclosed Strike: $10.72 | Not disclosed |
DisclosureSEC source: 0001683168-25-000855 · ownership.xml · derivative · entry 5 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,030 shares Expires 2027-12-14 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:37 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerStock Option (right to buy) · Derivative | 19,675 | Not disclosed Strike: $6.87 | Not disclosed |
DisclosureSEC source: 0001683168-25-000855 · ownership.xml · derivative · entry 4 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,030 Underlying: Common Stock · 19,675 shares Expires 2027-01-09 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:37 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerStock Option (right to buy) · Derivative | 19,600 | Not disclosed Strike: $5.22 | Not disclosed |
DisclosureSEC source: 0001683168-25-000855 · ownership.xml · derivative · entry 3 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,705 Underlying: Common Stock · 19,600 shares Expires 2025-12-14 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:37 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $4.67 | Not disclosed |
DisclosureSEC source: 0001683168-25-000855 · ownership.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,305 Underlying: Common Stock · 75,000 shares Expires 2027-11-27 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:37 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerCommon Stock, $0.001 par value | 130,324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-25-000855 · ownership.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2 · price: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 21:23 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 512.56 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-000092 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,222.881 Underlying: Common Stock · 512.56 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 19:47 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 8,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-008801 · ownership.xml · derivative · entry 3 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,147 Underlying: Common Stock · 8,147 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 19:47 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 26,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-008801 · ownership.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,756 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 19:47 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 26,756 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-008801 · ownership.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:13 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 455.31 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-024729 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,602.646 Underlying: Common Stock · 455.31 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:34 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 492.317 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-019895 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,038.589 Underlying: Common Stock · 492.317 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 16:07 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantCommon Stock | 1,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013519 · form4.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,579.583 F1 · kind: Represents grant of restricted stock under Issuer's 2017 Stock Plan, as amended and restated. F2 · balance_after: Includes shares of restricted stock held under Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan. Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 20:03 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 527.894 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011563 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,442.127 Underlying: Common Stock · 527.894 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 31, 2023 Filed Jan 2, 2024 21:21 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 553.409 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-000135 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,798.645 Underlying: Common Stock · 553.409 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 19:30 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 26,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-23-008938 · ownership.xml · derivative · entry 3 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,756 Underlying: Common Stock · 26,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2023 shall fully vest on December 14, 2024, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2023 shall fully vest on December 14, 2024, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 19:30 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 9,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-23-008938 · ownership.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2022 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2023. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2022 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2023. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 19:30 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 9,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-23-008938 · ownership.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| September 30, 2023 Filed Oct 2, 2023 20:55 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 624.573 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-025017 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,120.83 Underlying: Common Stock · 624.573 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| September 21, 2023 Filed Sep 22, 2023 12:51 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | PurchaseCommon Stock, $0.001 par value | 20,000 | $9.53 | $190,696.00 |
DisclosureSEC source: 0001683168-23-006622 · ownership.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,956 F1 · price: Represents a weighted average purchase price per share. These shares were purchased at prices ranging from $9.46 to $9.54. The Reporting Person has provided to the Issuer, and hereby undertakes to provide the SEC staff or a security holder of the Issuer, upon request, information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:52 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 513.496 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020140 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,381.334 Underlying: Common Stock · 513.496 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| April 27, 2023 Filed May 1, 2023 16:11 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantCommon Stock | 1,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013859 · form4.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,817.941 F1 · kind: Represents grant of restricted stock under Issuer's 2017 Stock Plan, as amended and restated. F2 · balance_after: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan and Issuer's 2017 Stock Plan, as amended and restated, and shares held in a dividend reinvestment plan. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:57 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 477.077 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011958 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,773.643 Underlying: Common Stock · 477.077 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 22:17 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 500.891 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-000178 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,207.951 Underlying: Common Stock · 500.891 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 20:00 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 9,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-22-008495 · ownership.xml · derivative · entry 3 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 Underlying: Common Stock · 9,612 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: The RSUs granted to the reported person on December 14, 2022 shall fully vest on December 14, 2023, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: The RSUs granted to the reported person on December 14, 2022 shall fully vest on December 14, 2023, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 20:00 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 4,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-22-008495 · ownership.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2021 pursuant to the Issuer's non-employee director compensation program which fully vested on December 14, 2022. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2021 pursuant to the Issuer's non-employee director compensation program which fully vested on December 14, 2022. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 20:00 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 4,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-22-008495 · ownership.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 21:11 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 526.752 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-023284 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,621.08 Underlying: Common Stock · 526.752 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 19:45 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 453.389 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018456 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,016.756 Underlying: Common Stock · 453.389 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| April 28, 2022 Filed May 2, 2022 21:20 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantCommon Stock | 1,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012867 · form4.xml · nonDerivative · entry 1 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,358.102 F1 · kind: Represents grant of restricted stock under Issuer's 2017 Stock Plan, as amended and restated. F2 · balance_after: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 14:44 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 379.492 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010984 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,494.505 Underlying: Common Stock · 379.492 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 22:33 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 365.031 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-000161 · form4.xml · derivative · entry 2 Carleone Joseph · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,041.702 Underlying: Common Stock · 365.031 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:31 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 4,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-21-006434 · ownership.xml · derivative · entry 3 CARLEONE JOSEPH · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,632 Underlying: Common Stock · 4,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: The RSUs granted to the reporting person shall fully vest on December 14, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: The RSUs granted to the reporting person shall fully vest on December 14, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:31 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 2,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-21-006434 · ownership.xml · derivative · entry 2 CARLEONE JOSEPH · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2020 fully vested on December 14, 2021. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2020 fully vested on December 14, 2021. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:31 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 2,379 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-006434 · ownership.xml · nonDerivative · entry 1 CARLEONE JOSEPH · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 15:40 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 362.593 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026388 · form4.xml · derivative · entry 2 CARLEONE JOSEPH · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,618.767 Underlying: Common Stock · 362.593 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:17 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 381.527 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021234 · form4.xml · derivative · entry 2 CARLEONE JOSEPH · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,197.664 Underlying: Common Stock · 381.527 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 20:48 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantCommon Stock | 1,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014443 · form4.xml · nonDerivative · entry 1 CARLEONE JOSEPH · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,113.317 F1 · kind: Represents grant of restricted stock under Issuer's 2012 Non-Employee Directors Stock Plan. F2 · balance_after: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 22:01 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 423.397 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012640 · form4.xml · derivative · entry 2 CARLEONE JOSEPH · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,759.505 Underlying: Common Stock · 423.397 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 22:24 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantDeferred Stock · Derivative | 447.675 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-000223 · form4.xml · derivative · entry 2 CARLEONE JOSEPH · CIK 0001212515 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,274.883 Underlying: Common Stock · 447.675 shares Expires not disclosed F2 · derivative.exercise_price: Deferred stock converts to common stock on a one-for-one basis. F3 · kind: Deferral of director fees under Issuer's Directors' Deferred Compensation Plan. F4 · derivative.exercise_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. F4 · derivative.expiration_date: Shares of common stock will be issued upon termination of reporting person's service as a director of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.